QuantiFERON®-CMV assay for the assessment of cytomegalovirus cell-mediated immunity

Expert Rev Mol Diagn. 2011 Jan;11(1):17-25. doi: 10.1586/erm.10.109.

Abstract

Cytomegalovirus (CMV) infection has historically been a major complication among immunocompromised patients, such as solid-organ and stem-cell transplant recipients and patients with advanced HIV infection. While the introduction of antiretroviral therapy has almost eradicated CMV infection in HIV-infected patients, CMV disease remains a significant problem in transplant recipients once antiviral prophylaxis is discontinued. QuantiFERON(®)-CMV allows the assessment of cellular immunity against CMV by detecting the production of IFN-γ following in vitro stimulation with CMV antigens. Preliminary studies have shown a correlation between a lack of detectable cell-mediated immunity measured by the QuantiFERON-CMV assay and a higher incidence of CMV infection and disease in immunocompromised patients. Measurement of cell-mediated immunity against CMV appears to be a promising strategy to identify patients at highest risk for the development of CMV disease and, therefore, to individualize preventive strategies for CMV in transplant recipients.

MeSH terms

  • AIDS-Related Opportunistic Infections / diagnosis
  • AIDS-Related Opportunistic Infections / immunology
  • Antigens, Viral / immunology*
  • CD8-Positive T-Lymphocytes / immunology*
  • CD8-Positive T-Lymphocytes / metabolism
  • CD8-Positive T-Lymphocytes / virology
  • Cytomegalovirus / immunology*
  • Cytomegalovirus Infections / diagnosis
  • Cytomegalovirus Infections / immunology*
  • Epitopes, T-Lymphocyte
  • Humans
  • Immunity, Cellular
  • Immunocompromised Host
  • Interferon-gamma / biosynthesis*
  • Interferon-gamma / blood
  • Molecular Diagnostic Techniques / methods
  • Sensitivity and Specificity
  • Transplantation Immunology

Substances

  • Antigens, Viral
  • Epitopes, T-Lymphocyte
  • Interferon-gamma